|
End-of-day quote
30/09/2026
|
5-day change
|
1st Jan Change
|
|
18.20 CNY
|
+2.08%
|
 |
+1.28%
|
+3.29%
|
|
09-02 |
Jefferies Adjusts DaShenLin Pharmaceutical Group's Price Target to 15 Yuan From 12 Yuan, Keeps at Underperform
|
MT
| |
08-24 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026
|
CI
| |
04-24 |
Dashenlin Pharma's Q1 Profit Rises 11%
|
MT
| |
04-24 |
Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4%
|
MT
| |
04-23 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
04-23 |
Dashenlin pharmaceutical 2025 net profit up 35.0% y/y
|
RE
| |
04-23 |
Sipai Health to Sell Stake in Pharmacy Operator to Dashenlin Pharmaceutical For RMB 51.7 Million
|
MT
| |
04-22 |
DaShenLin Pharmaceutical Group Co., Ltd. signed a equity transfer agreement to acquire Sipai Zhihe Technology Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.
|
CI
| |
29/10/25 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
|
CI
| |
28/08/25 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
|
CI
| |
25/04/25 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
|
CI
| |
25/04/25 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
|
CI
| |
15/10/24 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
|
CI
| |
19/09/24 |
Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.
|
CI
| |
17/09/24 |
DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on May 7, 2024, has closed with 6,722,254 shares, representing 0.59% for CNY 100.72 million.
|
CI
| |
30/08/24 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024
|
CI
| |
02/07/24 |
Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.
|
CI
| |
06/05/24 |
DaShenLin Pharmaceutical Group Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on April 1, 2024.
|
CI
| |
28/04/24 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
|
CI
| |
27/04/24 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
|
CI
| |
05/03/24 |
Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares
|
MT
| |
22/01/24 |
DaShenLin Pharmaceutical Group Co., Ltd. cancelled the transaction announced on January 19, 2023
|
CI
| |
27/11/23 |
Dashenlin Pharmaceutical to Boost Stake in Local Pharmacy Chain to 66% For 30 Million Yuan
|
MT
| |
24/11/23 |
DaShenLin Pharmaceutical Group Co., Ltd. agreed to acquire 15% stake in Chongqing Wanjiayan Pharmacy Chain Co., Ltd from Chongqing Wanjiayan Health Industry Group Co., Ltd. and Bai Run for CNY 30 million.
|
CI
| |
29/10/23 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
|
CI
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
